Health Department-Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States
As of October 1, the number of confirmed cases of multisystem inflammatory syndrome in children (MIS-C) in the United States surpassed 1,000.
Since mid-May 2020, CDC has been tracking reports of multisystem inflammatory syndrome in children (MIS-C), a rare but serious condition associated with COVID-19. MIS-C is a new syndrome, and many questions remain about why some children and adolescents develop it after a COVID-19 illness or contact with someone with COVID-19, while others do not.
Last updated October 15, 2020
Total Confirmed Cases*
*Confirmed cases were reported in 44 states, New York City, and Washington, DC. Additional cases are under investigation.
- Most cases are in children and adolescents between the ages of 1 and 14 years, with an average age of 8 years.
- Cases have occurred in children and adolescents from <1 year old to 20 years old.
- More than 75% of reported cases have occurred in children who are Hispanic or Latino (394 cases) or Black, Non-Hispanic (339 cases).
- 98% of cases (1,079) tested positive for SARS CoV-2, the virus that causes COVID-19. The remaining 2% were around someone with COVID-19.
- Most children developed MIS-C 2-4 weeks after infection with SARS-CoV-2.
- Slightly more than half (56%) of reported cases were male.
MIS-C Cases by Jurisdiction
Since reporting began in mid-May, 44 states, New York City, and Washington, DC, have reported at least one case of MIS-C to CDC. Most of those jurisdictions have ten or fewer reported cases. Because of the small number of cases in most states and to protect the privacy of patients and their families, CDC is not reporting individual states’ case counts.
MIS-C Case Ranges by Territory, State, New York City, and Washington, DC*
*We defer to states to release additional information on cases as they choose.
Daily MIS-C Cases (Seven-Day Moving Average)
The graph shows the seven-day average number of MIS-C cases with date of onset between March 11 and October 7, 2020. The confirmed cases are reported nationally on a bi-weekly interval. The seven day average number of MIS-C cases initially peaked at approximately 16 cases between May 1 and May 16.
The grayed-out area represents the most recent six weeks of data, in which reporting of cases is still incomplete. The actual number of MIS-C cases during this period is likely larger and these numbers will increase as additional case reports are incorporated.
4 of the 1,097 confirmed cases were missing dates.
Race and Ethnicity of Reported MIS-C Cases
In addition to location of MIS-C cases, CDC is closely monitoring characteristics of MIS-C patients such as race, ethnicity and age. To date, the majority of MIS-C patients have been Hispanic/Latino or Non-Hispanic Black. Hispanic/Latino and Non-Hispanic Black populations are also disproportionately affected by COVID-19 overall. Additional studies into MIS-C are needed to learn why certain racial or ethnic groups may be affected in greater numbers and what risk factors may contribute to this phenomenon.
135 of the 1,097 cases did not report race/ethnicity data.
Age of MIS-C Reported Cases
Early in the pandemic, it appeared that children and adolescents were less likely than adults to be infected with SARS-CoV-2 and, if infected, most had mild to moderate illness. Then, MIS-C cases began to appear in children and adolescents weeks after they had COVID-19, and sometimes when a child or teen had no known prior SARS-CoV-2 infection. Current data indicate the average age of children with MIS-C is 8 years.
Children and adolescents appeared to be less likely than adults to be infected or to have severe illness early in the COVID-19 pandemic; however, as the outbreak has progressed, larger numbers of children and adolescents are getting infected. It’s unknown whether this increase in COVID-19 cases among children and adolescents will also increase cases of MIS-C. CDC and state partners will be monitoring for additional cases and will adapt MIS-C recommendations as needed.
CDC investigators are assessing reported cases and children and adolescent’s health outcomes to try to learn more about specific risk factors for MIS-C, how the illness progresses in children and adolescents, and how to better identify MIS-C and distinguish it from similar illnesses.
About the data
This page is updated on the first and third Friday of each month.
Reported by Jurisdiction’s Health Department
Data on this page are reported voluntarily to CDC by each jurisdiction’s health department. CDC encourages all jurisdictions to report the most complete and accurate information that best represents the data available in their jurisdiction.
Case Definition for Multisystem Inflammatory Syndrome in Children (MIS-C)
- An individual aged <21 years presenting with feveri, laboratory evidence of inflammationii, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND
- No alternative plausible diagnoses; AND
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms
iFever >38.0°C for ≥24 hours, or report of subjective fever lasting ≥24 hours
iiIncluding, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin
- Some individuals may fulfill full or partial criteria for Kawasaki disease but should be reported if they meet the case definition for MIS-C
- Consider MIS-C in any pediatric death with evidence of SARS-CoV-2 infection
Timing of reporting
Case reporting may be delayed due to limited capacity at local/state health departments and as CDC assesses data to ensure cases meet the MIS-C case definition.